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Abstract: Various noninvasive to minimally invasive techniques can be used for the 
  improvement of cutaneous changes seen with photoaging. These include dermabrasion,   chemical 
peels, ablative and nonablative lasers, and filler agents such as hyaluronic acid. However, the 
most common nonsurgical cosmetic procedure performed in the treatment of rhytides is injection 
with botulinum toxin. Its extensive safety history and relative ease of use by the practitioner has 
led to high satisfaction in millions of patients. Nonetheless, proper training of the fundamentals 
in injection technique, the choice of the appropriate candidate, and knowledge of potential 
adverse events are imperative to ensure a satisfactory and safe outcome.
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Dynamic facial lines can be interpreted as manifestations of negative emotions, fatigue, 
stress, and perceived aging. Such rhytides result as a combination of intrinsic skin 
aging, ultraviolet damage, and repetitive action of facial muscles. Of these, the most 
contributing force for the persistence of facial wrinkles is the repetitive contractions 
of the intrinsic muscles for facial expression. There are a variety of different treatment 
options available for facial lines including the use of filling agents such as hyaluronic 
acid, ablative and nonablative laser surgery, dermabrasion, chemical peels, and 
invasive surgery such as rhytidectomy. However, these procedures do not adequately 
address the underlying cause of dynamic wrinkles as evidenced by the persistence of 
facial lines after treatment. The understanding that muscular contraction contributes 
to etiology of facial lines, wrinkles, and furrows1 has broadened the treatment options 
for these facial cosmetic blemishes.
Botulinum toxin type A (BTX-A), a potent neurotoxin that irreversibly blocks 
presynaptic acetylcholine release, has been successfully employed to treat facial 
spastic conditions such as blepharospasm, strabismus, focal dystonias, spasmodic 
dysphonia, and achalasia.2 Consequently, many clinicians have noted improvement 
of facial rhytides in patients who received BTX-A for these spastic disorders. Indeed, 
while treating patients with blepharospasm, Carruthers and Carruthers first noted 
improvement of glabellar frown lines.3
A variety of other hyperkinetic facial lines such as crow’s feet, horizontal forehead 
lines, melolabial folds, and other hyperkinetic facial lines have been successfully treated 
with BTX-A.4,5 Currently there are two commercial formulations of BTX-A, Botox® 
(Allergan, Inc.) and Dysport™ (Medicis) approved in the United States. In 2002, Botox® 
Cosmetic was FDA approved for the temporary improvement in the appearance of 
moderate to severe glabellar lines associated with corrugator and/or procerus muscle Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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activity in adult patients aged 65 years or less. In 2009, 
Dysport was FDA approved for the same cosmetic indica-
tion as Botox Cosmetic. In addition, Bocouture®/Xeomin® 
is another BTX-A formulation that is marketed by Merz 
Pharmaceuticals (Frankfurt, Germany) and was approved in 
late 2009 in Germany for the treatment of glabellar lines in 
adults younger than 65 years of age.
Likewise, botulinum toxin type B (BTX-B) is another 
potent neurotoxin that has been employed to treat spastic 
conditions such as cervical dystonia. Myobloc®, the only 
commercial formulation of BTX-B, is manufactured by 
Solstice Neurosciences, Inc. and is FDA approved for the 
treatment of cervical dystonia but currently not approved in 
the United States for any cosmetic use. A variety of hyper-
kinetic facial lines have also been treated successfully with 
BTX-B.6–13
The focus of this review article is to investigate the 
pharmacology of botulinum toxins in the management of 
skin aging, efficacy studies pertaining to various types of 
botulinum toxins, the safety and tolerability of botulinum 
toxin, and physician and patient reported outcomes relating 
to satisfaction, preference, and convenience. Table 1 lists the 
highlights of the various approved botulinum toxins.
Pharmacology – structure  
and mechanism of action
There are seven serologically distinct types of botulinum 
neurotoxins, designated types A through G, which correspond 
to the strain of Clostridium botulinum that produces the 
specific toxin. These serotypes are all synthesized as single 
chain polypeptides with molecular weights of approximately 
150 kD and share a common structural organization which 
consists of one heavy chain (100 kD) and one light chain 
(50 kD) polypeptide that are linked by a single disulfide bond. 
All botulinum toxins inhibit acetylcholine release at the neu-
romuscular junction in a three-step process. The single-chain 
polypeptides are activated by proteases which are cleaved 
into a double chain consisting of the heavy chain and the 
light chain moieties.14 Upon cleavage, the heavy chain binds 
to a high affinity receptor on the presynaptic nerve terminal 
which enables the internalization of the bound toxin into the 
cell. The light chain moiety is a zinc-dependant endopepti-
dase that cleaves membrane proteins responsible for docking 
acetylcholine vesicles on the inner side of the nerve terminal 
membrane.15 The cleavage of these proteins inhibits the fusion 
of the vesicles with the nerve membrane, thereby preventing 
release of acetylcholine into the neuromuscular junction.16
The intracellular target of BTX-A is the SNAP-25 
(  synaptosome-associated protein of molecular eight 25 kD) 
which is a protein essential for the successful docking and 
release of acetylcholine vesicles with the presynaptic   vesicle.17 
In contrast, BTX-B cleaves VAMP (vesicle associated mem-
brane protein), which is also known as synaptoabrevin.18 Like 
SNAP-25, VAMP is essential for the docking and fusion of the 
synaptic vesicles to the presynaptic membrane for the release 
of acetylcholine.
Cosmetic uses of botulinum toxin
Botox Cosmetic
Botox Cosmetic manufactured by Allergan Inc. was the first 
Type A botulinum toxin to be approved by the FDA in the 
United States. The product is supplied as a vacuum-dried 
  lyophilized power in vials containing either 50 U or 100 U 
of Botox Cosmetic. Unreconstituted Botox Cosmetic should 
be stored at 2–8°C. The official recommendation by the 
manufacturer is to reconstitute Botox Cosmetic with 2.5 mL 
of 0.9% nonpreserved saline for the 100 U vial (1.25 mL for 
the 50 U vial) to a final concentration of 4.0 U/0.1 mL. Prac-
titioners have also used other different dilutions ranging from 
1 to 10 mL/100 U and have reported that dilution at higher 
volumes can result in more diffusion. In addition, researchers 
have demonstrated no decrease in efficacy using preserved 
saline to dilute the Botox Cosmetic, although there is less 
pain experienced upon injection using preserved saline.19 The 
manufacturer recommends avoiding aggressive agitation of 
the vial upon mixing to prevent denaturation of the product. 
The reconstituted product should never be frozen and can be 
stored for up to six weeks at 4°C.
Table 1 Highlights of the various botulinum toxins
Botox Dysport Myobloc Bocouture/Xeomin
Type of botox A A B A
Manufacturer Allergan Medicis Solstice neuroscience Merz
FDA cosmetic approval Glabellar lines Glabellar lines None None (Approved in Germany for glabellar lines)
Other indications • Cervical dystonia 
• Blepharospasm 
• Strabismus 
• Axillary hyperhidrosis
• Cervical dystonia • Cervical dystonia • Cervical dystonia 
• BlepharospasmPatient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Tuberculin or insulin syringes are frequently used for 
injecting Botox Cosmetic since there is no potential space in 
the hub and result in less waste of the product. Either 30- and 
32-gauge needles are the most commonly used for injecting 
Botox Cosmetic.20 Topical anesthesia is not required but some 
patients may request this to minimize discomfort. The use of 
ice can also reduce pain and also minimize purpura formation 
by constricting the blood vessels prior to injection.
Prior to treating the patient with Botox Cosmetic, a 
complete medical history should be attained to prevent 
unwanted reactions.21 Medications and food products that 
inhibit platelet aggregation and increase clotting time should 
be discontinued for 10–14 days prior to the procedure. These 
include aspirin, nonsteroidal anti-inflammatories, garlic, 
and fish oils. Some medical conditions that are contrain-
dicated for botulinum toxin injections include peripheral 
motor neuropathic diseases or neuromuscular functional 
disorders, such as myasthenia gravis and Eaton-Lambert 
Syndrome. Patients who are currently taking aminoglyco-
side antibiotics such as gentamycin may develop increased 
inhibition of neuromuscular transmission and concomitant 
usage together with botulinum toxin is contraindicated. The 
presence of any infection or inflammation on the skin at the 
site of injection is also a contraindication. Finally, females 
who are pregnant or lactating should not receive injections 
of botulinum toxin.
The upper face
Facial wrinkles involving the forehead, glabella, and lateral 
periorbital regions are common aesthetic areas where botuli-
num toxin is injected. In treating the glabella, botulinum toxin 
targets thee bilateral corrugators, depressor supercilii, and the 
central procerus muscles that are responsible for the glabellar 
lines. Usually, two injections are administered per corrugator 
muscle and one injection in the procerus. The first phase 3 
study demonstrating the efficacy of Botox Cosmetic for the 
treatment of glabellar lines was published in 2002.22 Patients 
with moderate to severe glabellar lines at maximum frown 
received intramuscular injections of 20 U Botox Cosmetic 
or placebo into 5 glabellar sites. Patients were followed up 
for 120 days after injection. Outcome measures were physi-
cian ratings of glabellar line severity at maximum frown 
and rest, patient assessment of improvement, and vital sign 
and adverse event monitoring. A total of 264 patients were 
enrolled, with 203 receiving Botox Cosmetic and 61 in the 
placebo group. There was a significantly greater reduction 
in glabellar line severity with BTX-A than with placebo in 
all measures (P , 0.022) and the effect was maintained for 
many patients through to day 120. The recommended dos-
age for the treatment of glabellar lines is 20 U but can vary 
from 15–30 U depending on the strength of the corrugator 
and procerus muscles. Typically, men may need higher doses 
of botulinum toxin versus women given the greater strength 
of the muscles.
The treatment of the glabellar region with botulinum 
toxin results in a slight brow lift by weakening the central 
frontalis effect of brow elevation and thus proportionately 
increasing the frontalis effect of lateral brow elevation.23 An 
advanced technique that can be utilized to attain a lateral 
brow lift by weakening the lateral lid depressor muscles is 
to inject 1–2 U of Botox Cosmetic into the lateral-superior 
orbicularis muscle just below the lateral brow but above the 
superior orbital rim.
A single-center, prospective, double-blind, random-
ized, dose-comparison study was conducted in female 
patients between the ages of 18 and 65 years of age 
for the treatment of glabellar, forehead, and periorbital 
rhytides with Botox Cosmetic.5 Eligible patients were 
assigned randomly to 1 of 3 treatment groups represent-
ing total doses of 32, 64, or 96 U and were followed up 
for up to 52 weeks. Patients were required to have upper 
facial wrinkles that met the following specifications on a 
4-point facial wrinkle scale (FWS) (0 = none; 1 = mild; 
2 = moderate; and 3 = severe as determined at maximum 
attempted muscle contraction by a trained observer); 
moderate or severe glabellar lines; mild, moderate, or 
severe forehead lines; and bilaterally symmetric moderate 
or severe crow’s feet. The total dose was divided evenly 
among 16 injection sites: 5 injections in the glabellar, 
5 injections in the forehead, and 3 injections in each 
lateral canthal area for the periorbital wrinkles. Botox 
Cosmetic treatment, used in total doses of 32, 64, or 96 
U, was shown to be safe and effective for treating multiple 
upper facial rhytides in female patients in single sessions. 
Overall, each dose resulted in significant improvements 
in the appearance of facial rhytides, but a dose-response 
relationship emerged based on duration of effect and on 
between-group differences on a substantial number of the 
measures that were assessed. The principal differences 
between the groups were in the duration of the effect, 
although in some individuals, some areas wore off more 
rapidly than other areas. Based on anecdotal information, 
some physicians hypothesize that a longer duration of 
rhytide effacement may be achieved through treatment 
of multiple areas, as this eliminates any potential for 
adjacent muscle recruitment.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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When using botulinum toxin to treat forehead rhytides, 
typical doses of 15–30 U of Botox Cosmetic are injected into 
the frontalis muscle.24 Because the forehead is the primary 
brow elevator, care and caution must be exercised not to 
lower the eyebrows and flatten them when treating forehead 
wrinkles, especially in women where an arched brow is of 
aesthetic importance. To avoid lowering the brow, injecting 
higher up in the forehead can minimize this tendency as well 
as treating the glabella concomitantly. When treating the 
forehead for the first time, practitioners may reserve treating 
of the forehead area for 2 weeks after injecting the glabellar 
area first and also utilize a lower dose for the forehead to 
reduce the chance of depressing the brow excessively.
Typically, three injections are performed on each side of 
the lateral orbital of the eye to target the lateral orbicularis 
muscle to treat crow’s feet, with 2–3 U of Botox Cosmetic 
used per injection.25 The distance from the lateral canthus 
to the area of injection should be around 1–1.5 cm to 
minimize the rare occurrence of diplopia. In addition, the area 
around the lateral orbit is enriched with blood vessels and 
this is a site more prone to purpura. Care should be exercised 
to closely examine for the presence of blood vessels prior 
to injection. Sometimes after successful treatment of the 
crow’s feet, patients may note increased crinkling and fine 
rhytide formation immediately below the infraorbital area 
due to muscle recruitment. Should this occur, 1 U of Botox 
Cosmetic can be placed in the area of new wrinkle formation 
to obviate this effect. A study was conducted to compare the 
efficacy and safety of 4 doses of Botox Cosmetic with placebo 
to treat crow’s feet.4 Participants received a single bilateral 
treatment of 18, 12, 6, or 3 U of BTX-A or placebo injected 
into the lateral aspect of the orbicularis oculi muscle. Investi-
gators and participants rated crow’s feet severity at maximum 
smile on day 7 and at 30-day intervals from days 30 to 180. 
As observed by both investigators and subjects, all doses 
of BTX-A resulted in improvements in crow’s feet severity 
when compared with placebo. A dose-dependent treatment 
effect for efficacy was observed, with higher doses having 
an increased magnitude and duration of effect. However, a 
clear differentiation between the 18 U and 12 U doses was 
not apparent. It was concluded that BTX-A was safe and 
effective in decreasing the severity of crow’s feet, with 12 U 
per side suggested as the most appropriate dose.
Mid and lower face
The mid and lower face is not a common area to treat with 
botulinum toxin when compared to the upper face. Caution 
must be exercised in these areas since diffusion of toxin and 
inadvertent injection of adjacent musculature can result in 
functional deficits and unwanted limited motion.
Nasal wrinkles on the dorsum of the nose can frequently 
be treated with botulinum toxin by injecting a few units 
into the nasalis muscle. Between 2 and 5 U of botulinum 
toxin have commonly been used. A study was conducted to 
determine the efficacy of Botox Cosmetic in the treatment of 
nasal wrinkles of the superior nose (bunny lines).26 A total 
of 250 patients with nasal rhytides were treated and 3 U of 
Botox Cosmetic were injected bilaterally into the nasalis 
muscle. Patients were seen at 1 month for follow-up, and 
the remaining rhytides were documented. In total, 40% of 
patients had satisfactory treatment of nasal wrinkles with the 
initial bilateral 3-U injections. The remaining 60% still had 
nasal rhytides following the nasalis muscle injections. An 
additional 30% had persistent wrinkles at the root of the nose 
(nasal orbicular wrinkles), and 30% had wrinkles at the nasal 
root and between the eyes (nasociliary wrinkles). The injec-
tion of botulinum toxin into additional locations according 
to the anatomic differences of each person showed excellent 
resolution of the rhytides without complications.
Common areas in the lower half of the face to treat with 
botulinum toxin are the vertical perioral rhytides. These lines 
are caused by repeated contraction of the orbicularis oris. 
Several injections of 2 U of Botox Cosmetic can be placed 
along the upper and lower lip to minimize lip furrows. A study 
was conducted where 18 patients were injected with BTX-A 
into the vertical lip rhytides. The effect of treatment was 
evaluated at 2 to 3 weeks after procedure and smoothening 
of hyperfunctional lines and upper lip fullness/eversion was 
observed in patients treated with BTX-A injections.27
Another usage of botulinum toxin injections is to target 
the depressor anguli oris muscle of the mouth to elevate the 
corners of the mouth.28 The depressor anguli oris pulls down 
on the lateral oral commissures and excessive function causes 
the corners of the mouth to droop (marionette lines). The 
downward angle of the marionette lines can be improved 
by injecting 2–5 U of Botox Cosmetic intramuscularly 
approximately 8–10 mm lateral to the oral commissure and 
8–15 mm inferior to this point.
Relaxing the muscles of the mentalis can reduce the invol-
untary convolutions or dimpling of the chin when performing 
speaking or performing other mundane activities of the face.28 
In addition to softening the pebbling of the chin, injection 
of botulinum toxin into the mentalis can reduce the deep 
transverse labiomental crease that runs horizontally across 
the chin. A dose of 5–8 U of Botox Cosmetic is typically 
used to inject the mentalis muscle.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Cosmetic uses of botulinum toxin in the neck is primarily 
for the treatment of platysmal banding, or the vertical bands 
found in the central neck.29 Horizontal rhytides caused by 
contraction of the platysmal muscle, usually seen laterally, 
can be treated with botulinum toxin injections. The proper 
method to inject the platysma is to have the patient seated 
upright and contract the platysma. By doing so, the prac-
titioner can grasp the platysmal band between the thumb 
and index finger with the non-dominant hand and inject 
2–4 U of Botox Cosmetic in the lower dermis per injection 
site along the vertical extent of the band, starting approxi-
mately 2 cm below the inferior border of the mandible. The 
injections are repeated 1.5 to 2 cm apart from each other 
descending down the neck toward the border of the clavicle. 
Most patients will require several injection points to treat 
a platysmal band. It is advisable to inject no more than 40 
to 50 U of Botox Cosmetic total per treatment session for 
the platysmal bands.
Dysport
Dysport is used for the temporary improvement in the appear-
ance of moderate to severe glabellar lines   associated with 
procerus and corrugator muscle activity in adult patients less 
than 65 years of age.30 The recommendation for   reconstituting 
Dysport for glabellar lines in the 300 U vial is with 2.5 mL 
or 1.5 mL of unpreserved normal saline. The   recommended 
dosage for treating glabellar lines is a total dose of 50 U of 
Dysport divided in five equal aliquots of 10 U each to the 
procerus and corrugator muscles. Retreatment with Dysport at 
standard strength should be administered no more frequently 
than every 3 months. The potency units of Dysport are not 
interchangeable with other preparations of botulinum toxin 
products and, therefore, units of biological activity of Dysport 
cannot be compared to or converted into units of any other 
botulinum toxin products.31
The same anatomic areas that were described above to 
treat rhytides with Botox Cosmetic can also be applied with 
Dysport. A study was conducted to compare the efficacy 
and tolerability between Botox Cosmetic and Dysport in the 
treatment of moderate to severe glabellar lines.32 A total of 
62 patients with moderate or severe glabellar lines at maxi-
mum contraction were randomly assigned to receive 20 U 
of Botox Cosmetic or 50 U of Dysport (20% in the procerus 
muscle, 80% in the corrugator muscles). The incidence of 
patients with at least a 1-grade improvement in the   severity 
of their glabellar lines at maximum contraction peaked 
at week 8 in both groups. However, the duration of this 
improvement was generally more prolonged with Botox 
Cosmetic than with Dysport with the overall incidence of 
such   improvement being 77% versus 59% at week 12 and 
53% versus 28% at week 16. In addition, at week 16, the 
incidence of patients whose glabellar line severity was none 
or mild between Botox Cosmetic and Dysport was 23% 
versus 10% for all patients (not statistically significant) and 
50% versus 13% (P  = 0.05) for patients with moderate gla-
bellar lines at baseline. Throughout the 16-week follow-up, 
patients’ mean scores for how attractive they felt and how 
satisfied they felt with their appearance were consistently 
higher with Botox Cosmetic than Dysport, with statistical 
significance achieved for both at week 12. There was no 
significant between-group difference in the incidence of 
treatment-related adverse effects. It was shown that Botox 
Cosmetic offers more prolonged efficacy than Dysport when 
the two products were compared in a 2.5:1 dose ratio. At the 
2.5:1 dose ratio, the results of the study presented herein 
suggest that Botox Cosmetic offers more prolonged efficacy 
(and comparable tolerability) relative to Dysport. The data 
suggest that the dose of Dysport may need to be higher than 
the 50-U dose suggested for the treatment of glabellar lines 
to achieve a duration of effect and level of patient satisfaction 
that is comparable with Botox Cosmetic.
The results of five phase III studies of Dysport for the 
treatment of glabellar lines were recently published.33 Three 
double-blind, multicenter, randomized, placebo-controlled 
studies enrolled ethnically diverse healthy adults with glabel-
lar lines of at least moderate severity at maximum frown. In 
these studies, patients were followed for up to 180 days after 
treatment. The fixed-dose, single-treatment study random-
ized 158 patients to receive placebo or one dose of Dysport 
at 50 U. The fixed-dose, repeat-treatment study randomized 
311 patients to assess treatment following the prior Dysport 
treatment of 50 U. The variable-dose study randomized 
816 patients to receive placebo or a single variable dose 
(50–80 U, based on gender and assessment of muscle mass). 
Clinical evaluations were performed on days 14 and 30 and 
monthly thereafter. The primary endpoint was a response 
defined as a composite 2+ grade improvement, at day 30 
from baseline, on the wrinkle severity rating scale from 
2 to 0, or from 3 to 0 or 1 (where 3 = severe wrinkles/severe, 
2 =   moderate wrinkles/moderate, 1 = mild wrinkles/mild, and 
0 = no wrinkles/none), for both the blinded evaluators’/blinded 
investigators’ and patients’ assessments. Patients (1,116 total; 
720 Dysport, 396 placebo) given Dysport received 50 to 80 
U of treatment. The median duration of response was 85 days 
for fixed dosing and 109 days for variable dosing. Similar 
efficacy occurred at doses adjusted for gender and muscle Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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mass, although males required higher doses than females 
in the variable-dose study. Responses appeared as early as 
24 hours, with a median time to onset of 3 days. Extension 
studies evaluated 1,200 patients for 13 months and 768 
patients in an interim analysis for 24 months. Maintenance 
of efficacy was seen after multiple cycles, indicating a lack 
of tolerance. It was concluded that Dysport significantly 
improved moderate to severe glabellar lines compared with 
placebo, with onset seen as soon as 24 hours after treatment 
and a median duration of effect of 85 or 109 days for fixed 
or variable dosing, respectively.
In another study the efficacy of Dysport in treating 
crow’s feet in a double-blinded placebo controlled trial 
was examined.34 Participants with moderate to severe 
crow’s feet at maximum smile (mild to severe at rest) were 
randomized to a single bilateral Dysport treatment (15, 
30, or 45 U) or placebo. Independent panel assessments 
(Week 4) showed that all Dysport doses resulted in sig-
nificant improvements in crow’s feet severity at maximum 
smile (P , 0.001); a clear dose – response effect was 
seen. Improvement over placebo was seen in the 30-U and 
45-U groups at Week 12. Investigator assessment showed 
significant improvement for all doses for 12 weeks at 
maximum smile and rest (P # 0.01). Patient satisfaction 
was significantly greater for all doses than for placebo at 
16 weeks (all P , 0.05).
Myobloc
Myobloc is supplied as a sterile liquid formulation of the puri-
fied neurotoxin. Each vial contains 5,000 U/mL of botulinum 
toxin B in 0.05% human serum albumin, 0.01 M sodium 
succinate, and 0.1 M sodium chloride at a slightly acidic pH 
of approximately 5.6. Myobloc is available in three different 
total dosage strengths: 2,500, 5,000, and 10,000 U. The rec-
ommended storage condition for Myobloc is 2° to 8°C for up 
to 21 months and it must not be frozen; it can also be further 
diluted with normal saline. Myobloc is FDA approved for the 
treatment of cervical dystonia.
While not used as extensively as Botox Cosmetic or Dysport 
for cosmetic purposes, Myobloc may be used to treat facial 
rhytides in instances where patients develop loss of response 
to BTX-A. Repeated injections with BTX-A may result in the 
formation of neutralizing antibodies that may reduce the effec-
tiveness of subsequent treatments with BTX-A by inactivating 
the biological activity of the toxin. However, the rate of forma-
tion of neutralizing antibodies in patients receiving BTX-A has 
not been well studied and the critical factors for   neutralizing 
  antibody formation have not been well   characterized. 
The results from some studies suggest that botulinum toxin 
  injections at more frequent intervals or at higher doses may 
lead to greater incidence of antibody formation. In situations 
where patients develop intolerance to BTX-A, transitioning 
to Myobloc may lead to improved outcomes in the treatment 
of facial rhytides. A report demonstrated that BTX-B is an 
effective treatment modality for glabellar rhytides refractory 
or exhibiting decreased clinical efficacy to BTX-A.35
A study was published to observe the effects of 
BTX-B in comparison to BTX-A, on patients with brow 
  furrows   assessing initial efficacy and duration of effect.36 
Patients were injected with BTX-B in two different dose 
conversions against BTX-A to the corrugator-procerus 
complex. Some patients received a conversion of 50 U 
of BTX-B (a total of 1,000 U) to 1 U of BTX-A while 
others received a conversion of 100 U of BTX-B (a total 
of 2,000 U) to 1 U of BTX-A. The patients treated with 
BTX-A received a total of 20 U. Both types of botulinum 
toxin were effective at improving glabellar frown lines. 
The onset of actions occurred slightly sooner (2–3 days) 
with BTX-B than with BTX-A (3–7 days). Duration of 
effect with BTX-A was at least 16 weeks. The duration of 
response was dose dependent for BTX-B with 1,000 U of 
lasting 6–8 weeks and the higher dose of 2,000 U lasting 
10–12 weeks. At least with the doses used, BTX-B has a 
quicker onset of action but BTX-A has longer benefit for 
glabellar wrinkles. These data strongly suggest that further 
dose ranging studies of BTX-B are necessary using con-
trolled double blind studies in a larger patient population. In 
addition, there is a higher complaint of pain upon injection 
with Myobloc compared to Botox Cosmetic, presumably 
due to the lower pH of Myobloc.6,37
In other studies the treatment of glabellar wrinkles with 
BTX-B has also been investigated and a rapid onset of action 
but a shorter duration has been observed. A total of 1,800 U 
of BTX-B was used for the glabellar area and mean onset of 
1.5 days and a mean duration of 8 weeks was observed.12 At 
higher doses of BTX-B used by the same investigator in a 
follow-up prospective study, the duration of response was 9.6 
and 10.4 weeks with 2,400 and 3,000 U, respectively.12 The 
onset of action was seen within 2 to 3 days. Other researchers 
looked at three different dosages of BTX-B for the treatment 
of glabellar lines. Patients received either the low dose of 
1,875 U, the medium dose of 2,500 U, or the high dose of 
3,125 U.7 Most patients at all doses showed some evidence 
of paralysis at 2 months. At 3 months after injection, only 
participants in the high dose condition maintained a signifi-
cant response with BTX-B. The authors concluded that at Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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the doses utilized in their study, the effect of BTX-B does 
not generally appear to last as long as BTX-A. However, 
similar to the other studies, the onset of action was sooner 
with BTX-B.
Bocouture/Xeomin
Bocouture was approved in late 2009 in Germany for the 
treatment of glabellar lines in adults younger than 65 years 
of age. It is not available commercially in the United States. 
Unlike other neurotoxins, Bocouture does not contain protein 
complexes including bacterial proteins. Clinical trials have 
demonstrated that Bocouture is well tolerated and highly 
effective in treating the glabella lines and does not require 
refrigeration either during transport or in storage.
Safety of botulinum toxin
Cosmetic treatment with botulinum toxin injections has 
become one of the most common nonsurgical procedures 
performed by practitioners. It has been proven as safe and 
effective for the treatment of glabellar lines and other rhytides 
in the face and neck. Nonetheless, given its long safety track 
record and high usage in millions of patients, knowledge 
of any potential adverse effects associated with botulinum 
toxin is essential for any practitioner who performs such 
injections. Generalized reactions that have idiosyncratically 
occurred from botulinum toxin injections include nausea, 
fatigue, malaise, flu-like symptoms, and rashes at sites 
distant from the injection, but the instances of these events 
occurring is rare.
Age considerations
It is difficult to tell for sure whether patients over the age of 
65 respond differently to BTX-A than do younger patients 
since there have been no studies investigating cosmetic uses 
of BTX-A specifically in the elderly, and there have not been 
enough elderly patients enrolled in clinical studies to make any 
meaningful comparisons.38 Since the elderly are more likely to 
have thinner and less elastic skin, weaker facial muscles, and 
wrinkles that over time are caused by gravity-induced tissue 
sagging rather than muscle contraction, the elderly are not 
expected to respond as well to BTX-A treatment.39 The site 
of injection also warrants special considerations in the elderly. 
Treatment of forehead lines, for example, would require 
injections to the frontalis muscle, which many older people 
use to raise their eyebrows and eyelids to see. Older patients 
may also have redundant skin under the brow (pseudoptosis) 
which could be worsened by BTX-A   treatment. Older patients 
who receive BTX-A for glabellar lines may be more at risk 
for complications such as eyelid ptosis if they have a reduced 
or absent orbital septum.40 Conservative dosing, injection of 
low volumes, and proper placement of the injection can reduce 
the possibility of spread of the toxin to unintended muscles. 
A prudent method is to start at the lowest possible effective 
dose for elderly patients.
Diffusion
The effects of botulinum toxin effects, in some cases, may 
diffuse beyond the site of local injection.41 The symptoms are 
consistent with the mechanism of action of botulinum toxin 
and may include asthenia, generalized muscle weakness, 
diplopia, blurred vision, ptosis, and breathing difficulties. 
These symptoms have been reported hours to weeks after 
injection. To date, no definitive serious adverse event reports 
of distant spread of toxin effect associated with cosmetic use 
of botulinum toxin has been made.
Pre-existing neuromuscular disorders
Patients with peripheral motor neuropathic diseases, 
amyotrophic lateral sclerosis, or neuromuscular junctional 
disorders (myasthenia gravis or Lambert-Eaton syndrome) 
should be monitored particularly closely when given botuli-
num toxin.42 Patients with neuromuscular disorders may be 
at increased risk of clinically significant effects including 
severe dysphagia and respiratory compromise from typical 
doses of botulinum toxin injections.
Drug interactions
Concomitant administration of botulinum toxin and amino-
glycosides or other agents interfering with neuromuscular 
transmission (eg, curare-like nondepolarizing blockers, 
lincosamides, polymyxins, quinidine, magnesium sulfate, 
anticholinesterases, succinylcholine chloride) should be per-
formed with caution as the effect of the toxin may be potenti-
ated, resulting in excessive neuromuscular weakness.43
Pregnancy and lactation
Administration of botulinum toxin is not recommended 
  during pregnancy. There are no adequate and well-controlled 
studies of botulinum toxin in pregnant women. Caution 
should be exercised when botulinum toxin is administered to 
a nursing woman because it is not known whether this drug 
is excreted in human milk.43
Ptosis and asymmetry
Transient ptosis is the most frequently reported complication 
and has been reported in the literature in approximately 5% Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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of patients.40,44 Ptosis of the eyelid results from migration 
of the botulinum toxin to the levator palpebrae superioris 
muscle. The levator allows the eyelid to open properly and 
fully. To avoid ptosis, injections should occur at least 1 cm 
above the eyebrow and should not cross the midpupillary 
line. A therapy recommended to treat ptosis from administra-
tion of botulinum toxins A and B is the use of apraclonidine 
0.5% eye drops. The most common dosing scheme used 
for apraclonidine is one or two drops three times daily until 
ptosis resolves.
The most significant complication of treatment of the 
frontalis is brow ptosis. Injections in the forehead should 
always be above the lowest fold produced when the subject 
is asked to elevate their forehead (frontalis). If the patient 
has a low eyebrow, treatment of the forehead lines should be 
avoided, or limited to that portion of the forehead 4.0 cm or 
more above the brow.
The most common reported complications in the crow’s feet 
area are bruising, diplopia, ectropion, and an asymmetric smile 
due to injection of the zygomaticus major.40 If severe lower lid 
weakness occurs, an exposure keratitis may result. Treatment 
is symptomatic. These complications are avoided by injecting 
at least 1 cm outside the bony orbit or 1.5 cm lateral to the lat-
eral canthus, not injecting medial to a vertical line through the 
lateral canthus, and not injecting close to the inferior margin 
of the zygoma. Violating these boundaries has on occasion 
also resulted in diplopia due to medial migration of Botox and 
resultant paralysis of the lateral rectus muscle. Covering or 
patching the eye will alleviate some of the double vision.
Patient reported outcomes  
with botulinum toxin
In the field of cosmetic therapy, patient satisfaction is vital 
and patient perceptions of the success of treatment are influ-
enced both by their expectations before treatment and by their 
impressions of the clinical outcome. Patients’ perceptions of 
clinical outcome are complex, and patient evaluations that 
have previously been reported in clinical trials for glabellar 
lines have typically been broad-based general assessments, 
such as the global assessment of change in the appearance of 
glabellar lines or the general level of satisfaction with treat-
ment. Although these offer valuable insights into the patients’ 
overall perceptions, they may not address specific aspects 
of treatment that are of greatest importance to an individual 
patient – for example, some patients want to look younger, 
some want to be more attractive, some would like to feel bet-
ter about their appearance, some want to look more rested, 
and some want to avoid looking tired, stressed, or angry 
when this is not how they feel. To help evaluate the success 
of treatment in achieving individual goals such as these, it 
is necessary to use more detailed assessments of patient-
reported outcomes that evaluate these issues specifically.
Several patient-reported outcomes measures have been 
developed and utilized in clinical trials of botulinum toxin 
for the treatment of rhytides, including the Self-Perception 
of Age (SPA) measure and the Facial Line Outcomes (FLO) 
questionnaire. On the FLO questionnaire, patients rate the 
degree to which their facial lines bother them; make them 
look older than they would like; prevent them from having a 
smooth facial appearance; and make them look tired, stressed, 
or angry when that is not how they feel. In several clinical 
trials significant improvements in these outcomes have been 
demonstrated from baseline and versus placebo for the treat-
ment of multiple upper facial lines as well as for treating 
the glabella as a single region. These outcomes data help in 
understanding patient objectives and motivations, establish-
ing a treatment plan, and ensuring patient satisfaction.45
In one study it was demonstrated that Botulinum toxin 
type A showed significantly superior efficacy to placebo in 
terms of both glabellar line severity (at maximum contrac-
tion and at rest) and global assessment.46 The mean score 
from the FLO questionnaire was also significantly greater 
with botulinum toxin type A than placebo, indicating that 
patients’ perceptions of their appearance had been signifi-
cantly improved by botulinum toxin. This was reflected in 
the self-perception of age data, which showed that botuli-
num toxin resulted in more patients considering themselves 
to look younger than their current age and fewer patients 
considering themselves to look older than their current age. 
Furthermore, those who considered that they looked younger 
than their current age at Week 4 but not at baseline reported 
a large change in the perception of their age (from a median 
of 4 years older than their current age at baseline to 5 years 
younger than their current age at Week 4).
In this study it was demonstrated that botulinum toxin 
type A offers not only clinical efficacy but also efficacy in 
addressing aspects of treatment that are of particular impor-
tance to patients – such as their desire to improve their facial 
appearance, have a smoothness to their facial appearance, 
not look older than they want, and not look tired, stressed, 
and angry when this is not how they feel. As patient percep-
tions such as these are actually the greatest determinant of 
treatment success in everyday clinical practice than more 
objective evaluations of clinical improvement, it is reas-
suring to know that botulinum toxin type A delivers what 
patients most desire. Botulinum toxin type A can help Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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patients achieve specific goals of treatment, such as those 
described above.
In another study, the objective was to compare the effect 
of Botox Cosmetic with placebo on participant-reported 
outcomes and to assess the utility of 64 U of Botox Cosmetic 
to treat the entire upper face.47 A total of 40 female partici-
pants were randomized to receive 64 U of Botox Cosmetic 
or identical placebo injections (double-masked) divided 
among 16 sites of the upper face and were followed for 
12 weeks. Participants unimproved at Week 4 were eligible 
for open-label Botox Cosmetic treatment and were followed 
through Week 16. Main outcome measures were scores on 
seven items of the FLO questionnaire and results on the 
SPA questionnaire for assessing age of appearance relative 
to actual age. Botulinum toxin treatment increased the pro-
portion of participants who reported looking younger than 
their current age while placebo injections had no effect on 
age perception. Throughout the duration of the study, 75% 
of the botulinum toxin-treated patients reported looking 
younger. At 4 weeks after treatment, botulinum toxin-treated 
participants reported looking younger by 3 years compared 
with the perceived age at baseline.
In another study it was demonstrated that BTX-A treat-
ment for frown lines can also be used as a treatment for 
depression.48 A psychological mechanism for this effect 
is that relaxation of the frown muscles leads to less facial 
feedback for negative emotions. Consequently, a negative 
affect is harder to maintain and so the person has a more 
positive mood. In order to test this mechanism, the mood of 
patients who had received BTX-A treatment for glabellar 
frown lines was measured and compared with patients who 
had received other cosmetic treatments. The results showed 
that the BTX-A-treated patients showed a significantly less 
negative mood and supported the facial feedback view that 
frowning can make one unhappier. Treatments that prevent 
frowning correlate with reduced negative mood.
Conclusion
The aforementioned therapeutic uses of the various types of 
botulinum toxin formulations have expanded the ability of 
practitioners to treat various rhytides of the face and neck 
and to reverse the signs of aging. By specially targeting the 
hyperkinetic lines of the face, botulinum toxin has addressed 
a fundamental problem of recurring wrinkles that could not 
be adequately controlled with filler agents or laser treatment 
by themselves. When used as monotherapy or in combination 
with other treatment modalities, the use of botulinum toxin is 
a simple, minimally-invasive procedure that has minimal to 
no downtime, minimal adverse events, and has turned back 
the clock for millions of patients.
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